143 results
Page 4 of 8
8-K
EX-99.1
fstekwevfpmjgv53
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
8-K
EX-99.1
yh5m1s20t8f o9zqmd
6 Nov 19
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
7:35am
8-K
EX-99.1
u9tt5dv9172 hs
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am
8-K
EX-10.1
y72ypcrpto985t lbhz
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
7ew0b9uqcm3 y6q
25 Jul 19
Other Events
8:07am
8-K
EX-99.1
0k19 xzghxtr
18 Jul 19
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE-A4 to Enhance Antitumor Responses
8:11am
8-K
EX-99.1
o8prqi5woc7 h6w
15 May 19
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
8:11am
8-K
EX-99.1
9qpjkr6ch0ygv2 uewb
6 May 19
Adaptimmune TRANSFORMING T CELL THERAPY Clinical and Business Update
8:11am
8-K
EX-99.1
c5kts758
6 May 19
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
7:08am
8-K
EX-99.1
t6b7lxovghpja nd9l1t
2 Apr 19
Other Events
8:10am
8-K
r8d8 s4zibojwi5
2 Apr 19
Other Events
8:10am
8-K/A
EX-99.1
ouvdr8m2crcrxds06b
27 Feb 19
CORRECTING and REPLACING — Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
5:16pm